Oncology - CurrentMed

Oncology

Using Electronic Health Records to Classify Cancer Site and Metastasis

PMCID: PMC12176508 PMID: 40533095 DOI: 10.1055/a-2544-3117 Journal: Applied clinical informatics Publication Date: 2025-6-18 Authors: Kroenke K, Ruddy KJ, Pachman DR, Grzegorczyk V, Herrin J, et al. Key Points * Multiple EHR data extraction methods can effectively identify cancer site and metastatic status * 44.4% of patients were identified as

Oncology

PDGF‐D Promotes Epithelial–Mesenchymal Transition of Glioma Cells Through the NF‐κB/NOTCH1 Pathway

PMCID: PMC12175480 PMID: 40530904 DOI: 10.1002/cam4.71002 Journal: Cancer medicine Publication Date: 2025-6-18 Authors: Li Y, Zhao Y, Shi M, Ma X, Jia M, et al. Key Points * PDGF-D expression positively correlates with glioma malignancy and WHO tumor grade * Knockdown of PDGF-D significantly reduced colony formation by p

Oncology

MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT/mTOR Pathway

PMCID: PMC12175197 PMID: 40530890 DOI: 10.1002/cam4.71000 Journal: Cancer medicine Publication Date: 2025-6-18 Authors: Liang J, Li A, Chen J, Cao N, Zhu T, et al. Key Points * Let-7b-5p is significantly downregulated in HCC, associated with reduced patient survival (p = 0.04805) * Overexpression of Let-7b-5p decreased HCC cell

Oncology

Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway

PMCID: PMC12175380 PMID: 40528181 DOI: 10.1186/s12967-025-06697-8 Journal: Journal of translational medicine Publication Date: 2025-6-17 Authors: Jiang Z, Yang Y, Zhou J, Li X, Meng Q, et al. Key Points * Drp1 overexpression is a significant driver of ESCC growth and metastasis * High Drp1 expression correlates with poor patient prognosis

Oncology

Hypoxia‐induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9‐mediated GSK3β/β‐catenin signalling

PMCID: PMC12177104 PMID: 40534132 DOI: 10.1002/ctm2.70376 Journal: Clinical and translational medicine Publication Date: 2025-6-18 Authors: Xu J, Wu L, Chen T, Liu Y, Zhang Y, et al. Key Points * Elevated PGK1 levels correlate with poor survival and advanced tumor stages in ESCC patients * PGK1 promotes tumor progression

Oncology

Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine

PMCID: PMC12173229 PMID: 40526688 DOI: 10.1371/journal.pone.0326029 Journal: PloS one Publication Date: 2025-6-17 Authors: Shaykevich A, Chae D, Silverman I, Goel S, Maitra R Key Points * Carbamazepine and oncolytic reovirus demonstrate synergistic effects in inducing autophagy in KRAS-mutated colorectal cancer cells * Dual treatment significantly increased autophagy-related protein

Oncology

AKR1C2 silencing promotes ferroptosis and inhibits proliferation, migration, and invasion in lung cancer cells

PMCID: PMC12176218 PMID: 40531841 DOI: 10.1371/journal.pone.0325995 Journal: PloS one Publication Date: 2025-6-18 Authors: Cui Y, Liu Z Key Points * AKR1C2 expression is significantly higher in lung cancer tissues and correlates with worse patient prognosis * High AKR1C2 expression is associated with increased lymph node metastasis and advanced

Oncology

PI3K-dependent GAB1/Erk phosphorylation renders head and neck squamous cell carcinoma sensitive to PI3Kα inhibitors

PMCID: PMC12177050 PMID: 40533463 DOI: 10.1038/s41419-025-07767-x Journal: Cell death & disease Publication Date: 2025-6-18 Authors: Zhang X, Xu J, Wang X, Xu L, Zhang X, et al. Key Points * CYH33 demonstrates potent anti-proliferative activity against HNSCC, including cisplatin-resistant cell lines * Achieved significant tumor growth inhibition in xenograft models

Oncology

ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer

PMCID: PMC12175430 PMID: 40528239 DOI: 10.1186/s13046-025-03435-2 Journal: Journal of experimental & clinical cancer research : CR Publication Date: 2025-6-18 Authors: Xu K, Chen H, Zhu X, Li H, Liu X, et al. Key Points * High ESRP1 expression is an independent prognostic factor for improved survival in diffuse-type gastric cancer

Oncology

The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma

PMCID: PMC12178006 PMID: 40533802 DOI: 10.1186/s12967-025-06704-y Journal: Journal of translational medicine Publication Date: 2025-6-18 Authors: Zhou X, Cui G, Hu E, Wang X, Tang D, et al. Key Points * A six-gene DNL signature effectively stratifies HCC patients into distinct prognostic risk groups * Predictive model shows high accuracy with

Oncology

EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis

PMCID: PMC12174314 PMID: 40527884 DOI: 10.1038/s41419-025-07771-1 Journal: Cell death & disease Publication Date: 2025-6-17 Authors: Yuan F, Wang Y, Yuan L, Tang T, Ye L, et al. Key Points * EGFRvIII mutation is associated with higher WHO grade 4 gliomas (93.3% vs. 53.6%, p=0.044) * M2

Pharmacology

[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial

PMCID: PMC12175455 PMID: 40528226 DOI: 10.1186/s13063-025-08921-8 Journal: Trials Publication Date: 2025-6-17 Authors: Ruijters VJ, Snijders TJ, van der Pol JA, van de Giessen EM, Niers JM, et al. Key Points * First comprehensive randomized trial investigating FET PET's utility in differentiating pseudoprogression from true tumor progression in